187 related articles for article (PubMed ID: 1482139)
1. Activity of MS-8209, a nonester amphotericin B derivative, in treatment of experimental systemic mycoses.
Saint-Julien L; Joly V; Seman M; Carbon C; Yeni P
Antimicrob Agents Chemother; 1992 Dec; 36(12):2722-8. PubMed ID: 1482139
[TBL] [Abstract][Full Text] [Related]
2. In-vivo therapeutic efficacy in experimental murine mycoses of a new formulation of deoxycholate-amphotericin B obtained by mild heating.
Petit C; Chéron M; Joly V; Rodrigues JM; Bolard J; Gaboriau F
J Antimicrob Chemother; 1998 Dec; 42(6):779-85. PubMed ID: 10052902
[TBL] [Abstract][Full Text] [Related]
3. In vitro renal toxicity and in vivo therapeutic efficacy in experimental murine cryptococcosis of amphotericin B (Fungizone) associated with Intralipid.
Joly V; Farinotti R; Saint-Julien L; Chéron M; Carbon C; Yeni P
Antimicrob Agents Chemother; 1994 Feb; 38(2):177-83. PubMed ID: 8192439
[TBL] [Abstract][Full Text] [Related]
4. In-vitro and in-vivo evaluation of a new amphotericin B emulsion-based delivery system.
Tabosa Do Egito ES; Appel M; Fessi H; Barratt G; Puisieux F; Devissaguet JP
J Antimicrob Chemother; 1996 Sep; 38(3):485-97. PubMed ID: 8889723
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of water-soluble pneumocandin analogs L-733560, L-705589, and L-731373 with mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis.
Abruzzo GK; Flattery AM; Gill CJ; Kong L; Smith JG; Krupa D; Pikounis VB; Kropp H; Bartizal K
Antimicrob Agents Chemother; 1995 May; 39(5):1077-81. PubMed ID: 7625792
[TBL] [Abstract][Full Text] [Related]
6. Efficacies of amphotericin B-desoxycholate (Fungizone), liposomal amphotericin B (AmBisome) and fluconazole in the treatment of systemic candidosis in immunocompetent and leucopenic mice.
van Etten EW; van den Heuvel-de Groot C; Bakker-Woudenberg IA
J Antimicrob Chemother; 1993 Nov; 32(5):723-39. PubMed ID: 8125837
[TBL] [Abstract][Full Text] [Related]
7. Amphotericin B lipid complex therapy of experimental fungal infections in mice.
Clark JM; Whitney RR; Olsen SJ; George RJ; Swerdel MR; Kunselman L; Bonner DP
Antimicrob Agents Chemother; 1991 Apr; 35(4):615-21. PubMed ID: 2069367
[TBL] [Abstract][Full Text] [Related]
8. Treatment of murine candidiasis and cryptococcosis with amphotericin B incorporated into egg lecithin-bile salt mixed micelles.
Brajtburg J; Elberg S; Travis SJ; Kobayashi GS
Antimicrob Agents Chemother; 1994 Feb; 38(2):294-9. PubMed ID: 8192455
[TBL] [Abstract][Full Text] [Related]
9. Complexing amphotericin B with gold nanoparticles improves fungal clearance from the brains of mice infected with Cryptococcal neoformans.
Chintalacharuvu KR; Matolek ZA; Pacheco B; Carriera EM; Beenhouwer DO
Med Mycol; 2021 Nov; 59(11):1085-1091. PubMed ID: 34332505
[TBL] [Abstract][Full Text] [Related]
10. Treatment of experimental systemic mycoses with BRL 49594A.
Najvar LK; Luther MF; Graybill JR
J Antimicrob Chemother; 1995 Dec; 36(6):1005-1011. PubMed ID: 8821599
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model.
Olson JA; Adler-Moore JP; Schwartz J; Jensen GM; Proffitt RT
Antimicrob Agents Chemother; 2006 Jun; 50(6):2122-31. PubMed ID: 16723574
[TBL] [Abstract][Full Text] [Related]
12. Comparison of amphotericin B and N-D-ornithyl amphotericin B methyl ester in experimental cryptococcal meningitis and Candida albicans endocarditis with pyelonephritis.
Perfect JR; Durack DT
Antimicrob Agents Chemother; 1985 Dec; 28(6):751-5. PubMed ID: 4083860
[TBL] [Abstract][Full Text] [Related]
13. Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis.
Brogden RN; Goa KL; Coukell AJ
Drugs; 1998 Sep; 56(3):365-83. PubMed ID: 9777313
[TBL] [Abstract][Full Text] [Related]
14. A novel injectable water-soluble amphotericin B-arabinogalactan conjugate.
Falk R; Domb AJ; Polacheck I
Antimicrob Agents Chemother; 1999 Aug; 43(8):1975-81. PubMed ID: 10428922
[TBL] [Abstract][Full Text] [Related]
15. The in-vivo activity of an antifungal antibiotic, benanomicin A, in comparison with amphotericin B and fluconazole.
Ohtsuka K; Watanabe M; Orikasa Y; Inouye S; Uchida K; Yamaguchi H; Kondo S; Takeuchi T
J Antimicrob Chemother; 1997 Jan; 39(1):71-7. PubMed ID: 9044030
[TBL] [Abstract][Full Text] [Related]
16. Amphotericin B and amphotericin B methyl ester ascorbate. I. Chemotherapeutic activity against Candida albicans, Cryptococcus neoformans, and Blastomyces dermatitidis in mice.
Gadebusch HH; Pansy F; Klepner C; Schwind R
J Infect Dis; 1976 Nov; 134(5):423-7. PubMed ID: 792355
[TBL] [Abstract][Full Text] [Related]
17. N-acetylcysteine reduces amphotericin B deoxycholate nephrotoxicity and improves the outcome of murine cryptococcosis.
Magalhães TFF; Costa MC; Holanda RA; Ferreira GF; Carvalho VSD; Freitas GJC; Ribeiro NQ; Emídio ECP; Carmo PHF; de Brito CB; de Souza DG; Rocha CEV; Paixão TA; de Resende-Stoianoff MA; Santos DA
Med Mycol; 2020 Aug; 58(6):835-844. PubMed ID: 31919505
[TBL] [Abstract][Full Text] [Related]
18. Toxicity and therapeutic efficacy of amphotericin B delivered through cholesterol hemisuccinate vesicles in the treatment of experimental murine aspergillosis.
Saxena S; Khan JA; Ghosh PC
J Antimicrob Chemother; 1998 Nov; 42(5):635-42. PubMed ID: 9848448
[TBL] [Abstract][Full Text] [Related]
19. Improvement of amphotericin B activity during experimental cryptococcosis by incorporation into specific immunoliposomes.
Dromer F; Barbet J; Bolard J; Charreire J; Yeni P
Antimicrob Agents Chemother; 1990 Nov; 34(11):2055-60. PubMed ID: 2073097
[TBL] [Abstract][Full Text] [Related]
20. Polymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice.
Espuelas MS; Legrand P; Campanero MA; Appel M; Chéron M; Gamazo C; Barratt G; Irache JM
J Antimicrob Chemother; 2003 Sep; 52(3):419-27. PubMed ID: 12888593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
